First Welsh Patient Receives Personalized mRNA Cancer Vaccine in Groundbreaking Trial
• A 65-year-old colorectal cancer patient from Cardiff has become the first person in Wales to receive a personalized mRNA cancer vaccine designed to prevent disease recurrence.
• The innovative trial, led by Velindre Cancer Centre in partnership with BioNTech, utilizes similar technology to COVID-19 vaccines to create patient-specific treatments targeting individual cancer profiles.
• The study aims to enroll approximately 110 Welsh patients across multiple UK centers, representing a significant step forward in personalized cancer immunotherapy development.
© Copyright 2025. All Rights Reserved by MedPath